Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Other Accumulated Expenses (2016 - 2020)

Historic Other Accumulated Expenses for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $111000.0.

  • Larimar Therapeutics' Other Accumulated Expenses changed N/A to $111000.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $111000.0, marking a year-over-year change of. This contributed to the annual value of $508000.0 for FY2019, which is 12780.27% up from last year.
  • Larimar Therapeutics' Other Accumulated Expenses amounted to $111000.0 in Q3 2020.
  • In the past 5 years, Larimar Therapeutics' Other Accumulated Expenses ranged from a high of $508000.0 in Q4 2019 and a low of $56000.0 during Q3 2016
  • Over the past 5 years, Larimar Therapeutics' median Other Accumulated Expenses value was $111000.0 (recorded in 2016), while the average stood at $182882.4.
  • In the last 5 years, Larimar Therapeutics' Other Accumulated Expenses crashed by 6335.62% in 2016 and then surged by 14000.0% in 2018.
  • Larimar Therapeutics' Other Accumulated Expenses (Quarter) stood at $110000.0 in 2016, then fell by 4.55% to $105000.0 in 2017, then skyrocketed by 112.38% to $223000.0 in 2018, then skyrocketed by 127.8% to $508000.0 in 2019, then tumbled by 78.15% to $111000.0 in 2020.
  • Its Other Accumulated Expenses was $111000.0 in Q3 2020, compared to $464000.0 in Q2 2020 and $236000.0 in Q1 2020.